Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · IEX Real-Time Price · USD
22.82
-0.22 (-0.95%)
At close: Jul 19, 2024, 4:00 PM
22.87
+0.05 (0.22%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Rocket Pharmaceuticals Employees
Rocket Pharmaceuticals had 268 employees as of December 31, 2023. The number of employees increased by 28 or 11.67% compared to the previous year.
Employees
268
Change (1Y)
28
Growth (1Y)
11.67%
Revenue / Employee
n/a
Profits / Employee
-$930,276
Market Cap
2.07B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 268 | 28 | 11.67% |
Dec 31, 2022 | 240 | 89 | 58.94% |
Dec 31, 2021 | 151 | 60 | 65.93% |
Dec 31, 2020 | 91 | 34 | 59.65% |
Dec 31, 2019 | 57 | 24 | 72.73% |
Dec 31, 2018 | 33 | 13 | 65.00% |
Dec 31, 2017 | 20 | -4 | -16.67% |
Dec 31, 2016 | 24 | 7 | 41.18% |
Dec 31, 2015 | 17 | 12 | 240.00% |
Dec 31, 2014 | 5 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
BrightSpring Health Services | 35,000 |
Addus HomeCare | 34,846 |
LifeStance Health Group | 9,325 |
Premier | 2,800 |
10x Genomics | 1,259 |
STAAR Surgical Company | 1,115 |
Beam Therapeutics | 507 |
Catalyst Pharmaceuticals | 167 |
RCKT News
- 23 days ago - FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment - Investopedia
- 24 days ago - Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) - Business Wire
- 7 weeks ago - Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy - Business Wire
- 2 months ago - Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) - Business Wire
- 2 months ago - Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress - Business Wire
- 3 months ago - Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia - Business Wire
- 4 months ago - Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team - Business Wire
- 5 months ago - Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress - Business Wire